Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enterotoxigenic Escherichia coli colonization factor antigen I fimbrial antigen (CFA/I fimbrial antigen) is a surface adhesive pilus (fimbria) expressed by ETEC, a pathogenic E. coli strain that causes acute watery diarrhea, especially in children and travelers. CFA/I fimbriae consist of a major stalk subunit (CfaB) and a minor tip adhesin (CfaE), forming helical filaments mediating robust, host-specific adhesion to glycosphingolipid receptors on the intestinal epithelium. This adhesive interaction initiates colonization and subsequent pathogenicity, making CFA/I a critical virulence factor and a validated target for vaccine and anti-adhesion therapeutic development. CFA/I belongs to the class 5 fimbriae family, shares structural features with other bacterial pili, and displays antigenic variation in exposed regions to evade host immunity. Blockade of CFA/I—by antibodies or vaccine-induced immune responses—prevents bacterial attachment, colonization, and disease progression. Expression profiling and immunoassays detect CFA/I as a diagnostic marker in clinical ETEC isolates. Notable challenges include antigenic variability and coverage, as well as the absence of approved small-molecule drugs targeting this antigen directly.
Adhesion inhibition (blocking interaction between CFA/I fimbriae and host glycosphingolipids); Immune neutralization by antibody binding to CfaB or CfaE and preventing adhesion/colonization; Vaccine-induced immune memory against CFA/I tip or stalk proteins
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enterotoxigenic Escherichia coli colonization factor antigen I fimbrial antigen (CFA/I fimbrial antigen).